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( 597) polymorphisms and IL-6 levels with hepatitis B virus
related HCC risk in Indian population.
Methods: Five groups of subjects were enrolled viz. control
(n = 100), HBV-carriers (n = 60), chronic active HBV (n = 60),
HBV-cirrhotic (n = 60) and HBV-related HCC (n = 53). PCR-
RFLP was performed to study various polymorphic forms of
IL-6 and levels in PBMCs were estimated by ELISA. Genotype
distributions were compared using chi square analysis and
the odds ratios (ORs) and 95%CI were calculated to express
the relative risk.
Results: In IL-6 ( 572), the GC genotype, was in negative
association (p < 0.001) with HCC, among controls, while it
was a signiﬁcant risk factor (p < 0.001) for the same, among
HBV-carriers. In contrast, the CC genotype was a risk factor
(p < 0.001) for progression the disease to cirrhosis among
controls and HBV-carriers (OR: 3.2 and 4.0 respectively).
In case of IL-6( 597), GA genotype signiﬁcantly increased
(p < 0.001) HCC risk, both among controls and HBV-carriers.
The IL-6 levels were found to be signiﬁcantly lower in all the
diseased groups, with reference to controls. However, levels
were signiﬁcantly higher in cirrhotic group when compared
with the carrier and active hepatitis group. Moreover, in
both IL-6( 572) and ( 597) heterozygotes were found to
have lower IL-6 levels as compared to those having wild
genotypes.
Conclusions: Polymorphic forms of IL-6 and basal IL-6
levels share a strong association with HBV-HCC risk in
Indian population and thus should be further evaluated
as candidate genes to determine individual susceptibility
for the same.
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Objectives: Evaluate the efﬁcacy of Tiaoganjanpihexue (a
traditional Chinease medicine term) CHM-prescription for
treating a 31-year-old female HBeAg(+) chronic hepatitis B
Chinese patient with suboptimal response to Adefovir
Dipivoxil (AD) for 63 weeks switch to AD + lamivudine (LVD)
for 18 weeks, and to AD for 45 weeks, and to Telbivudine
(TEB) for 24 weeks. Modeling the dynamics of the anti-HBV
infection treatments.
Methods: During 2007 2010, the patient was treated
by AD, AD+LVD, AD and TEB continuously. Her baseline
characteristics were HBV DNA = 3.48×107 cps/ml, ALT
= 103.2 I/U, HBeAg = 1.400 S/CO, Anti-HBe = 0.213S/CO
and those at week 150 were HBV DNA <1000 cps/ml,
ALT <14 I/U (over 100 weeks), HBeAg = 3.840S/CO, Anti-
HBe = 1.061S/CO. After 16 weeks’ stopping treatment, her
HBV DNA was returned to 6.8×103 and other characteristics
were almost the same as those at week 150. Using the CHM
Tiaoganjanpihexue (consisting of 21 ingredients) treated the
patient, two times daily and decoction after meals.
Results: After 4 weeks’ treatment her HBeAg and anti-
HBe reduced to 0.850S/CO and 0.528S/CO. Following
21 weeks’ addtional treatments, her HBeAg had been kept
seroconversion and HBV DNA reduced to 1.40×103 cps/ml.
During the 25 week’s Tiaoganjanpihexue therapy, her mean
ALT = 19.03 I/U. A mathematical new model is introduced to
model the dynamics of the anti-HBV infection treatment.
The simulated curve is in good agreement with the clinic
tested patient’s HBV DNA.
Conclusions: The CHM Tiaoganjanpihexue has a speciﬁc
function that is able to activate patient’s immune function
to suppress HBV directly but not injure the patient’s
hepatocytes.
Acknowledgments: This work is jointly supported by the 11th
5-Year Plan Key Research Project of China (No. 2008ZX10500-
006) and the NNSF of China (No.61074192).
PP-111 Hepatitis B virus (HBV) subgenotypes and
mutations in core promoter and precore/core
and their clinical implications in Xinjiang Uighur
patients
X.F. Sun1 *, Y.X. Zhang1, S.J. Wen2, J.L. Hou2, H. Liu1,
Z.H. Wang2. 1First Afﬁliated Hospital, Xinjiang Medical
University, 2Nanfang Hospital, Nanfang Medical University,
China
Objective: To detecte HBV subtypes, mutation of core
promoter and precore/core and clinical features among
Xinjiang Uygur patients with chronic HBV infection.
Methods: PCR-RFLP was used to detect the subtypes, core
promoter and precore/core of HBV in 109 Uygur patients
with chronic HBV, and analyses of the relationship between
mutation and clinical features.
Results: In 109 Uygur patients with chronic HBV group, there
were 9 cases with HBV genotype B infection who were HBV
Ba subtype, 50 cases with HBV genotype C and 27 cases
with C1 subtype i, 23 cases with C2 subtype, 32 cases
with C/D recombinant i, 18 cases with HBV genotype D
infection. According to the progress of the HBV infection,
G1896A mutation in HBV precore or core region had no
signiﬁcant difference in chronic hepatitis B and cirrhosis,
but A1762T/G1764A mutation in the HBV subtype C1 and C2
and i Ba have signiﬁcantly increased in cirrhosis.we fund that
A1762T/G1764A mutation in HBV C/D recombinant infection
is low.
Conclusion: Uygur patients with CHB have more HBV C/D
recombinant, and C1 subtype infection. A1762T/G1764A
mutation in the HBV subtype C1 and C2 subtypes have
signiﬁcantly increased.
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Objective: Previous studies showed that HBV genotype
correlated with HBV transmission, clinical disease spectra,
progression, prognosis, antiviral effect, etc. This study
is aimed to evaluate the clinical signiﬁcance of HBV
genotype.
Methods: HBV genotypes were analyzed in 280 patients
infected with hepatitis B virus. Liver function, HBV markers
including PreS1, HBV DNA levels and T cell subsets of these
patients were also measured.
Results: HBV genotyping had a geographical distribution.
Genotype C was mainly prevalent in patients from north
china while Genotype B from south china. In the progression
of asymptomatic carrier or acute hepatitis to chronic
hepatitis, liver cirrhosis and liver cancer, genotype C
increased while genotype B decreased. Genotype C and
genotype BC showed lower levels in prealbum (Pre-A)
and album (ALB) and lower ratio of album to globulin
(A/G) than genotype B (P= 0.02, P= 0.03, P= 0.01 and
P= 0.005, P= 0.001, P< 0.001, respectively), but showed
higher levels in globulin (GLO) than genotype B (P< 0.001
and P= 0.01, respectively). Genotype C showed lower levels
in cholinesterase (CHE) than genotype B (P= 0.007). There
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was no signiﬁcant difference among HBV genotypes in the
levels of alanine transferase (ALT), aspartate transferase
(AST), total bilirubin (TBIL), gamma-glutamyl transferase
(GGT), alkaline phosphatase (ALP), total bile acid (TBA). The
positive rates of PreS1 antigen of genotype C and genotype
BC were high (72.3% and 67.3%, respectively) while that
of genotype B was low (29%). On the contrary, genotype C
(24.6%) and genotype BC (26.1%) indicated lower negative
rates of PreS1 antigen than genotype B (67.1%).
Conlusions: HBV genotypes had a geographical distribution.
Genotype C showed more serious liver dysfunction than
genotype B and was easier to develop into chronic hepatitis,
liver cirrhosis and liver cancer. Further study was needed
to know why genotype C has high PreS1 positive rate while
genotype B has high PreS1 negative rate.
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Objective: To study the relation and clinical signiﬁcance
between chronic HBV infection and myocardial injury.
Methods: To retrospective analyze the clinical date of
93 chronic HBV infection patients from January 2010 to
February 2011 in Xinjiang two centers.
Results: Between the four groups of chronic hepatitis B,
chronic severe hepatitis B, the compensatory stage of
hepatitis B liver cirrhosis, the decompensatory stage of
hepatitis B liver cirrhosis: (1) The patients had elevated
enzymes, the abnormally high rate of chronic hepatitis B
severe hepatitis group and hepatitis B cirrhosis group is
higher than other two groups, but the difference was
not statistically signiﬁcant (P> 0.05). (2) In 93 patients,
the electrocardiograms of 7 patients were abnormally,
accounting for 7.53%. They are 2 cases of sinus bradycardia,
1 case of anteroseptal myocardial disease to be ranked,
1 case of anteroseptal myocardial ischemia, 1 case of left
branch block and 1 case of incomplete left bundle branch
block. Before 6 cases were from chronic hepatitis B group,
the last one case from hepatitis B cirrhosis group. (3) Among
93 patients, 52 patients had abnormal manifestation of
cardiac color Doppler ultrasound, accounting for 55.91%.
But the abnormal manifestation had different abnormalities
during the patients in different groups, and most patients
had multiple abnormalities. Compare other three groups,
the chronic hepatitis B group had higher incidence rate of
mitral and tricuspid regurgitation detected in the systolic.
the chronic hepatitis B group had statistical signiﬁcant with
chronic severe hepatitis B group (P< 0.05), and no statistical
signiﬁcant with hepatitis B liver cirrhosis group (P> 0.05).
Conclusion: Chronic HBV infection can occur in myocardial
injury, can be expressed as abnormal manifestation
in myocardial enzymes, electrocardiogram, cardiac
color Doppler ultrasound, may lead to HBV-related
cardiomyopathy. If the chronic HBV infected patients
combined of myocardial injury, may be appropriate
to relax the anti-viral indications, meanwhile give
protect myocardium treatment actively to delay disease
progression.
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Aim: To identify the role of HBV in the pathogenesis and
prognosis of intrahepatic cholangiocarcinoma (ICC) by a
retrospective study.
Methods: Ninety-seven ICC patients (59 males and 38
females) were divided into three groups: Group I:
HBsAg-positive and anti-HBc-positive (n = 26); Group II:
HBsAg-negative and anti-HBc-positive (n = 50); Group III:
HBsAg-negative and anti-HBc-negative (n = 21). The
clinicopathologic features were compared and analyzed.
Results: Compared with Group III, the mean age (P = 0.018)
and the positive rate of CA19 9 (>37U/ml) (P = 0.000) of
Group I were signiﬁcantly lower, while the positive rate of
AFP (>25 ng/ml) (P = 0.012), PT value (P = 0.030), hepatic
cirrhosis (P = 0.001) and the account of poor differentiation
(P = 0.028) were signiﬁcantly higher. In addition, patients
of Group I had worsen outcome compared to Group II and
Group III (P = 0.010).
Conclusion: ICC patients infected by HBV tend to develop
tumor at earlier age, be AFP positivea nd CA19 9
negative, get hepatic cirrhosis, have higher PT value, poor
differentiation and worsen outcome. HBV-associated ICC and
HCC may hold common disease process for carcinogenesis.
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Background and Aim: Cellular immune mechanisms
involving T cell reaction are considered to be signiﬁcantly
involved in the pathogenesis of hepatitis B virus (HBV)
infection. Many studies have independently revealed that
Treg cells and Th17 cells played antagonism role in chronic
HBV infection, and imbalance between Treg and Th17 exist
in chronic HBV infection. These prompted us to investigate
whether the Treg/Th17 balance altered during HBV infection
and, if it did, what cytokine circumstances could contribute
to this change.
Methods: The serum concentration of Treg/Th17
differentiation-related cytokines in 18 patients with chronic
hepatitis B (CHB), 17 patients with acute-on-chronic
hepatitis B liver failure (ACHBLF), 10 patients with
acute hepatitis B (AHB), 12 asymptomatic HBV carriers,
and 10 normal controls was measured by enzyme-linked
immunosorbent assay (ELISA). Peripheral population of Th17
and Treg cells was analyzed by ﬂow cytometric assay.
Results: Compared with normal controls, patients with
acute liver inﬂammation had environments prone to
Th17 cells differentiation, and accompanied with higher
frequency of Th17 cells and higher level of IL-17A.
The ratios of Tregs to Th17 cells in CHB and ACHBLF
patients were signiﬁcantly lower than those in normal
controls and asymptomatic HBV carriers. The frequency of
Th17 cells or the serum IL-17A levels were signiﬁcantly
correlated with liver injury and HBV load in patients
with HBV infection. Furthermore, the Treg/Th17 ratio was
signiﬁcantly correlated with liver injury and HBV load in
patients with HBV infection, too.
